Research Triangle Park, NC – According to filings with the U.S. Securities and Exchange Commission, Incyclix Bio is raising $29,999,917.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Patrick Roberts played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Incyclix Bio
Incyclix Bio, LLC (previously Arc Therapeutics, LLC) is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.

To learn more about Incyclix Bio, visit http://incyclixbio.com/

Contact:
Patrick Roberts, Chief Executive Officer
919-328-0003
patrick@incyclixbio.com
https://www.linkedin.com/in/pjroberts77/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved